Protalix BioTherapeutics (PLX) Return on Sales (2010 - 2026)

Protalix BioTherapeutics has reported Return on Sales for 17 years, with the latest figure at 0.01% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales rose 1.0% year-over-year to 0.01%; the trailing twelve-month figure through Mar 2026 stood at 0.0% (changed 0.0% YoY), and the FY2025 full-year result was 0.0%, changed 0.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.01%, up from 0.0% in the prior quarter.
• The five-year high for Return on Sales was 0.01% in Q4 2024, with the low at 0.02% in Q4 2023.
• Average Return on Sales over 5 years is 0.0%, with a median of 0.0% recorded in 2023.
• Year-over-year, Return on Sales decreased 2 bps in 2023 and gained 3 bps in 2024.
• Tracing PLX's Return on Sales over 5 years: stood at 0.0% in 2022, then slumped by 534 bps to 0.02% in 2023, then soared by 125 bps to 0.01% in 2024, then tumbled by 180 bps to 0.0% in 2025, then jumped by 215 bps to 0.01% in 2026.
• The last three Return on Sales figures came in at 0.01% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025), per Business Quant data.

Peer Comparison